Po-Han Lin1,2, Shin-Cheh Chen3, Ling-Ming Tseng4, King-Jen Chang5, Ai-Chu Huang1, Kuo-Chih Cheng1, Karen Yang1,6, Hui-Chen Wu7, Tsu-Yi Chao8, Yuan-Ching Chang9, Peng-Chan Lin10, Wen-Hung Kuo5, Wen-Lin Kuo3, Ching-Hung Lin11, Huo-Mu Chen5, Dah-Cherng Yeh12, Liang-Chih Liu13, Chun-Yu Liu14, Ming-Yang Wang5, Chiao Lo5, Yen-Shen Lu11, Chiun-Sheng Huang15. 1. Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan. 2. Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan. 3. Department of Surgery, Chang Gung Memorial Hospital, Taoyun, Taiwan. 4. Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan. 5. Department of Surgery, College of Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. 6. Department of Molecular Biology, Princeton University, Princeton, NJ, USA. 7. Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, USA. 8. Division of Hematology/Oncology, Shuang-Ho Hospital, Taipei Medical University, Taipei, Taiwan. 9. Department of Surgery, MacKay Memorial Hospital and Mackay Medical College, Taipei, Taiwan. 10. Department of Oncology, National Cheng Kung University, Tainan, Taiwan. 11. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. 12. Department of Surgery, Chung Kang Branch, Cheng Ching Hospital, Taichung, Taiwan. 13. Department of Surgery, China Medical University Hospital, Taichung, Taiwan. 14. Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. 15. Department of Surgery, College of Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. huangcs@ntu.edu.tw.
Abstract
PURPOSE: Breast cancer is increasing around the globe, including Asia. We aimed to examine the survival and risk of contralateral breast cancer (CBC) in Asian breast cancer patients with BRCA mutations. METHODS: A total of 128 breast cancer patients with germline BRCA mutations and 4,754 control breast cancer patients were enrolled. Data on clinical-pathologic characteristics, survival, and CBC were collected from the medical record. The rates of survival and CBC were estimated by Kaplan-Meier method. RESULTS: The mean age of onset in BRCA mutation carriers was significantly younger than control patients (BRCA vs. Non-BRCA: 43.9 vs. 53.2 years old). BRCA mutation carriers had a higher proportion of triple-negative breast cancer (TNBC) (52%) than control patients (12%, p < 0.001). The risk of CBC was significantly higher in BRCA mutation patients than in control cases (hazard ratio (HR) = 3.95, 95% CI 2.71-5.75); when stratified by genotype, the HRs (95%CI) were 4.84 (3.00-7.82) for BRCA1 and 3.13 (1.78-5.49) for BRCA2 carriers, respectively. Moreover, BRCA1 mutation patients with triple-negative breast cancer (TNBC) as their first breast cancer had the highest risk of CBC (HR = 5.55, 95% CI 3.29-9.34). However, we did not observe any differences in relapse-free survival and overall survival between mutation carriers and control patients. CONCLUSION: Our study suggest that BRCA patients had a significantly higher risk of developing CBC, particularly for BRCA1 mutation carriers with TNBC as the first breast cancer.
PURPOSE: Breast cancer is increasing around the globe, including Asia. We aimed to examine the survival and risk of contralateral breast cancer (CBC) in Asian breast cancer patients with BRCA mutations. METHODS: A total of 128 breast cancer patients with germline BRCA mutations and 4,754 control breast cancer patients were enrolled. Data on clinical-pathologic characteristics, survival, and CBC were collected from the medical record. The rates of survival and CBC were estimated by Kaplan-Meier method. RESULTS: The mean age of onset in BRCA mutation carriers was significantly younger than control patients (BRCA vs. Non-BRCA: 43.9 vs. 53.2 years old). BRCA mutation carriers had a higher proportion of triple-negative breast cancer (TNBC) (52%) than control patients (12%, p < 0.001). The risk of CBC was significantly higher in BRCA mutation patients than in control cases (hazard ratio (HR) = 3.95, 95% CI 2.71-5.75); when stratified by genotype, the HRs (95%CI) were 4.84 (3.00-7.82) for BRCA1 and 3.13 (1.78-5.49) for BRCA2 carriers, respectively. Moreover, BRCA1 mutation patients with triple-negative breast cancer (TNBC) as their first breast cancer had the highest risk of CBC (HR = 5.55, 95% CI 3.29-9.34). However, we did not observe any differences in relapse-free survival and overall survival between mutation carriers and control patients. CONCLUSION: Our study suggest that BRCA patients had a significantly higher risk of developing CBC, particularly for BRCA1 mutation carriers with TNBC as the first breast cancer.
Authors: Mary B Daly; Robert Pilarski; Matthew B Yurgelun; Michael P Berry; Saundra S Buys; Patricia Dickson; Susan M Domchek; Ahmed Elkhanany; Susan Friedman; Judy E Garber; Michael Goggins; Mollie L Hutton; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison W Kurian; Christine Laronga; Jennifer K Litton; Julie S Mak; Carolyn S Menendez; Sofia D Merajver; Barbara S Norquist; Kenneth Offit; Tuya Pal; Holly J Pederson; Gwen Reiser; Kristen Mahoney Shannon; Kala Visvanathan; Jeffrey N Weitzel; Myra J Wick; Kari B Wisinski; Mary A Dwyer; Susan D Darlow Journal: J Natl Compr Canc Netw Date: 2020-04 Impact factor: 11.908
Authors: Bernadette A M Heemskerk-Gerritsen; Matti A Rookus; Cora M Aalfs; Margreet G E M Ausems; Johanna M Collée; Liesbeth Jansen; C Marleen Kets; Kristien B M I Keymeulen; Linetta B Koppert; Hanne E J Meijers-Heijboer; Thea M Mooij; Rob A E M Tollenaar; Hans F A Vasen; Maartje J Hooning; Caroline Seynaeve Journal: Int J Cancer Date: 2014-07-08 Impact factor: 7.396